



[E1]




[도2]



[도3]




[E4]




[圖5]




[도6]




[도 7]




[도8]




[도9]




[도10]




[도11]




[Figure 12]




[Figure 13]




[도14]



[515]




[도16]

1: Recombinant A β 42


2. 3X TG

3. 3X TG with AAV-hSyn-V18P/F19D/A21D-Tau inhibitor #1

[도 17]




[도18]




1: AAV-hSyn

2: AAV-hSyn-Aβ (V18P/F19D/A21D)-Tau inhibitor #1(서열번호 22)

[도19]




[도20]



1: AAV-hSyn

2: AAV-hSyn-Aβ (V18P/F19D/A21D)-Tau inhibitor #1(서열번호 22)


[도21]




1: AAV-hSyn

2: AAV-hSyn-Aβ (F V18P/F19D/A21D)-hSyn-Tau inhibitor #1

[도22]



[도 23]



- 1: AAV-hSyn (Control),
 2: AAV- hSyn-A β (V18P/F19D/A21D),
 3: AAV- hSyn-A β (V18P/F19D/A21D)-hSyn-Tau inhibitor #1
 4: AAV- hSyn-A β (V18P/F19D/A21D)-hSyn-Tau inhibitor #2

